CN101531629A - 由消旋的马来酸氨氯地平制备左旋氨氯地平的方法 - Google Patents
由消旋的马来酸氨氯地平制备左旋氨氯地平的方法 Download PDFInfo
- Publication number
- CN101531629A CN101531629A CN200910030828A CN200910030828A CN101531629A CN 101531629 A CN101531629 A CN 101531629A CN 200910030828 A CN200910030828 A CN 200910030828A CN 200910030828 A CN200910030828 A CN 200910030828A CN 101531629 A CN101531629 A CN 101531629A
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- preparation
- levamlodipine
- water
- alkali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 42
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 41
- HTIQEAQVCYTUBX-KRWDZBQOSA-N (S)-amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-KRWDZBQOSA-N 0.000 title claims abstract description 32
- 229950008554 levamlodipine Drugs 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 28
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract 7
- 239000003513 alkali Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 230000006340 racemization Effects 0.000 claims description 7
- 238000001291 vacuum drying Methods 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000012069 chiral reagent Substances 0.000 abstract description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract description 3
- 239000012046 mixed solvent Substances 0.000 abstract description 3
- 238000001556 precipitation Methods 0.000 abstract description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 abstract 1
- 150000007529 inorganic bases Chemical class 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 239000007787 solid Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- -1 2-amino ethoxy Chemical group 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RWNVSUBMXHALNE-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;methylsulfinylmethane Chemical compound CS(C)=O.OC(=O)C(O)C(O)C(O)=O RWNVSUBMXHALNE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002213 calciumantagonistic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
Landscapes
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910030828 CN101531629B (zh) | 2009-04-17 | 2009-04-17 | 由消旋的马来酸氨氯地平制备左旋氨氯地平的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200910030828 CN101531629B (zh) | 2009-04-17 | 2009-04-17 | 由消旋的马来酸氨氯地平制备左旋氨氯地平的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101531629A true CN101531629A (zh) | 2009-09-16 |
CN101531629B CN101531629B (zh) | 2010-12-29 |
Family
ID=41102510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200910030828 Active CN101531629B (zh) | 2009-04-17 | 2009-04-17 | 由消旋的马来酸氨氯地平制备左旋氨氯地平的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101531629B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102266331A (zh) * | 2011-08-19 | 2011-12-07 | 海南锦瑞制药股份有限公司 | 一种含有左旋氨氯地平和氯沙坦钾的全新药用组合物及其制备方法 |
CN102516159A (zh) * | 2011-12-15 | 2012-06-27 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种苯磺酸左旋氨氯地平的生产方法 |
CN103044314A (zh) * | 2013-01-06 | 2013-04-17 | 先声药业有限公司 | 马来酸氨氯地平的制备方法 |
CN111777547A (zh) * | 2020-07-17 | 2020-10-16 | 江西施美药业股份有限公司 | 一种诱导析晶拆分左旋氨氯地平的方法 |
CN113087656A (zh) * | 2020-01-09 | 2021-07-09 | 鲁南制药集团股份有限公司 | 一种无定型苯磺酸左旋氨氯地平 |
-
2009
- 2009-04-17 CN CN 200910030828 patent/CN101531629B/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102266331A (zh) * | 2011-08-19 | 2011-12-07 | 海南锦瑞制药股份有限公司 | 一种含有左旋氨氯地平和氯沙坦钾的全新药用组合物及其制备方法 |
CN102266331B (zh) * | 2011-08-19 | 2012-12-26 | 海南锦瑞制药股份有限公司 | 一种含有左旋氨氯地平和氯沙坦钾的全新药用组合物及其制备方法 |
CN102516159A (zh) * | 2011-12-15 | 2012-06-27 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种苯磺酸左旋氨氯地平的生产方法 |
CN103044314A (zh) * | 2013-01-06 | 2013-04-17 | 先声药业有限公司 | 马来酸氨氯地平的制备方法 |
CN113087656A (zh) * | 2020-01-09 | 2021-07-09 | 鲁南制药集团股份有限公司 | 一种无定型苯磺酸左旋氨氯地平 |
CN113087656B (zh) * | 2020-01-09 | 2024-05-07 | 鲁南制药集团股份有限公司 | 一种无定型苯磺酸左旋氨氯地平 |
CN111777547A (zh) * | 2020-07-17 | 2020-10-16 | 江西施美药业股份有限公司 | 一种诱导析晶拆分左旋氨氯地平的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101531629B (zh) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101531629B (zh) | 由消旋的马来酸氨氯地平制备左旋氨氯地平的方法 | |
US6646131B2 (en) | Resolution of the enantiomers of amlodipine | |
CN101643469A (zh) | 一种盐酸巴尼地平的合成工艺 | |
CN104418841B (zh) | 一种光学纯雷贝拉唑及其钠盐的制备方法 | |
CN102659672B (zh) | 高纯度苯磺酸左旋氨氯地平的制备方法 | |
KR101235116B1 (ko) | 광학활성 암로디핀 겐티세이트 염의 제조방법 | |
CN101798280B (zh) | 一种手性拆分消旋体氨氯地平制备s-(-)-氨氯地平和r-(+)-氨氯地平的方法 | |
CN102850347B (zh) | 一种吡唑衍生物或其盐的拆分方法 | |
CN103193779A (zh) | 一种右佐匹克隆的制备方法 | |
KR100488384B1 (ko) | 신규한제조방법 | |
CN101528697B (zh) | 从外消旋氨氯地平分离s-(-)-氨氯地平的方法 | |
CN101570506A (zh) | 一种新的制备手性氨氯地平的方法 | |
KR101001646B1 (ko) | (r)-(+)-란소프라졸의 제조방법 및 이에 사용되는 중간체 | |
CN103819399B (zh) | 一种生产高纯度甘露六烟酯的方法 | |
CN102219729B (zh) | 光学纯的1,4-二氢-2,6-二甲基-4-(3-硝基苯)3,5-吡啶二羧酸 2-[(3,3-二苯基丙基)甲胺基]-1,1-二甲基甲酯的制备方法 | |
CN101357901B (zh) | 手性1,4-二氢-4-(3-硝基苯基)-3,5-吡啶二羧酸酯及其制备方法与其制备药物的应用 | |
CN102093284B (zh) | 富集哌啶-2-甲酰苯胺类旋光化合物的方法 | |
US7678921B2 (en) | Method for the enantiomoeric separation of optical active amlodipine | |
CN111100064A (zh) | 一种从废液中富集、回收和拆分碱性手性药物氨氯地平的方法 | |
CN100436417C (zh) | 一种光学活性氨氯地平的拆分方法 | |
CN1442407A (zh) | 光学纯的非索非那定及其盐酸盐的化学拆分制备法 | |
CN102070624A (zh) | 一种盐酸噻加宾的合成方法及无水盐酸噻加宾的制备方法 | |
KR100868160B1 (ko) | S-(-)-암로디핀 또는 이의 염의 제조방법 및 이에사용되는 중간체 | |
CN103012264A (zh) | 3-取代氨基-六氢-1h-氮杂环庚烷的拆分方法 | |
KR20100063915A (ko) | 높은 광학적 순도의 s-(-)-암로디핀을 제조하는 방법 및 그 중간생성 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SIMCERE PHARMACEUTICAL CO., LTD. JIANGSU SIMCERE P Free format text: FORMER OWNER: SIMCERE PHARMACEUTICAL CO., LTD. Effective date: 20150819 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150819 Address after: 210042 Xuanwu Avenue, Jiangsu, Nanjing, No. 699 -18 Patentee after: Jiangsu Simcere Pharmaceutical Research Company Limited Patentee after: Simcere Pharmaceutical Co., Ltd. Patentee after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu Avenue, Jiangsu, Nanjing, No. 699 -18 Patentee before: Jiangsu Simcere Pharmaceutical Research Company Limited Patentee before: Simcere Pharmaceutical Co., Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160912 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee after: Jiangsu Simcere Pharmaceutical Co., Ltd. Patentee after: Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu Avenue, Jiangsu, Nanjing, No. 699 -18 Patentee before: Jiangsu Simcere Pharmaceutical Research Company Limited Patentee before: Simcere Pharmaceutical Co., Ltd. Patentee before: Jiangsu Simcere Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18 Co-patentee after: Hainan Simcere Pharmaceutical Co., Ltd. Patentee after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18 Co-patentee before: Simcere Pharmaceutical Co., Ltd. Patentee before: Jiangsu Simcere Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |